A5027087424- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Genetic factors in colorectal cancer
- Sarcoma Diagnosis and Treatment
- Urologic and reproductive health conditions
- Health Systems, Economic Evaluations, Quality of Life
- Urological Disorders and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Genital Health and Disease
- Fibroblast Growth Factor Research
- Cancer-related gene regulation
- Global Cancer Incidence and Screening
- Esophageal Cancer Research and Treatment
- Cancer Diagnosis and Treatment
SUNY Upstate Medical University
2016-2025
Palmetto Hematology Oncology
2017
Trinitas Regional Medical Center
2015
Seton Hall University
2015
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, abiraterone acetate plus prednisone (AAP) prolong survival in the metastatic setting. We evaluated whether intensification of androgen-deprivation therapy (ADT) improves outcomes BRPC. PATIENTS AND METHODS PRESTO is randomized phase III, open-label trial patients BRPC ≤9 months...
Importance Tumor mutational burden (TMB) is a putative biomarker of efficacy for immune checkpoint inhibitor (ICI) therapies solid tumors, but not specifically penile squamous cell carcinoma (PSCC). Objective To characterize features and ICI therapy outcomes associated with high TMB in PSCC the routine clinical practice setting. Design, Setting, Participants In this cohort study, 397 cases were analyzed to identify genomic alterations more than 300 cancer-associated genes signatures,...
We investigated the association between race and FT among previous patients with cancer. Studies show that cancer experience financial toxicity (FT) because of their treatment.Data on individuals a history were collected in this cross-sectional study during 2012, 2014, 2017, from US Health Information National Trends Survey. This survey is conducted by mail monetary compensation as an incentive. specifically assessed responses to two questions: Has hurt you financially? Have been denied...
480 Background: Despite recent advances in treatment of EGAC, prognosis continues to be poor with reported 5-year survival less than 30%. EGAC is more frequently diagnosed at an old age the median diagnosis around 65 years. However, approximately 10% are a younger 50 years and those patients present advanced stages resulting worse prognosis. Our study investigated genomic landscape under 30 better understand characteristics occurring very young population. Methods: 8,001 cases clinically who...
630 Background: Metastatic CCAs have poor prognosis. Comprehensive genomic profiling (CGP) was used to compare alterations (GA) in phCCA, with cbdCCA, gbCCA and iCCA. Frequencies of GA therapy targets such as FGFR2, IDH, ERBB2 & BRAF, Immuno-oncology (IO) drug response predictors (MSI status, TMB PDL1) were examined. Methods: DNA extracted from 110 cases 743 2983 9178 ihCCA underwent hybrid capture based CGP evaluate classes (GA), MSI levels, ancestry, signature, HRD score germline...
210 Background: CAPC arising in young patients is a challenging disease with significant need for improvements systemic therapies, especially surgically incurable disease. Here we sought to explore the genomic landscape generate hypotheses and inform clinic trial design. Methods: 13 cases of men under age 39 years (CAPC <39) 23,364 50 or older >50) underwent comprehensive profiling (CGP) examine all classes alterations (GA). MSI high status, tumor mutation burden (TMB) levels, ancestry...
824 Background: CAPSCC is a challenging disease with significant need for improvements in effective systemic therapies patients surgically incurable disease. Methods: 373 cases of underwent comprehensive genomic profiling to examine all classes alterations (GA). MSI high status, tumor mutation burden (TMB) levels, ancestry and trinucleotide mutational signatures were determined from the sequencing data. HRDsig status was calculated using broad set genome-wide copy number features (PMID...
564 Background: Kidney tumors (KT) comprises approximately 4% of all new cancer cases in US per year, with about a third being de-novo metastatic. 5-Methylthioadenosine phosphorylase (MTAP) is key enzyme the methionine salvage pathway & has emerged as putative biomarker for synthetic lethality-based trials testing Protein Arginine Methyltransferase 5 (PTMT5) Metastasis-associated protein 2 (MTA2) inhibitors. We compared genomic landscape KT vs without MTAP loss (del). Methods: From...
666 Background: CAUBC (any patients with node positive, metastasis positive or inoperable T4 disease) arising in YOUC is a challenging disease significant need for improvements systemic therapy especially surgically incurable disease. Methods: 9,411 cases of underwent comprehensive genomic profiling (CGP) to examine all classes alterations (GA). MSI high status, tumor mutation burden (TMB) levels, ancestry and trinucleotide mutational signatures were determined from the sequencing data....
535 Background: Although both U and NU bladder adenoCA share several histological similarities, they differ in site of origin optimal treatment paradigms. They are relatively resistant to conventional cisplatin-based chemotherapy surgical resection is the only curative option for organ-confined stages. The purpose this study investigate differences genomic alterations (GA) between these tumor types, with aim identifying potential therapy targets. Methods: A total 133 328 were analyzed from a...
The term "financial toxicity" or "hardship" is a patient-reported outcome that results from the material costs of cancer care, psychological impacts these costs, and coping strategies patients use to deal with strain includes delaying forgoing care. However, little known about impact financial toxicity on screening. We examined effects screening tests for prostate colon cancer. hypothesized greater hardship would show an association decreased prevalence screening.This cross-sectional...
443 Background: Electronic cigarette smoking and similar novel modalities have raised questions about their impact on various cancers compared with traditional forms of tobacco smoking. Tobacco has been concretely proven to increase the risk many cancers, including lung (LCa) bladder (BCa) cancer. To date, there is little data how e-cigarette impacts incidence these cancers. We investigated whether any disparities exist in prevalence LCa BCa between histories using a US nationally...
Early-stage NSCLC, encompassing resectable stage I-III [1] are curable, and represents 25% of all lung cancers [2]. The management non-metastatic NSCLC is a rapidly changing area clinical oncology.
Advanced bladder squamous cell carcinoma (aBSCC) is an uncommon form of urinary malignancy when compared with the much higher urothelial incidence. We studied genomic alteration (GA) landscape in a series aBSCC based on association human papilloma virus (HPV) to determine if differences GA would be observed between positive and negative groups.
450 Background: Inactivating genomic alterations (GA) of FANCC gene are associated with instability, DNA cross-linking, and homologous repair deficiency (HRD). GA most frequently colon, lung, breast, prostate cancers (0.5% frequency) germline mutations linked to familial breast cancer. have been rarely RT not currently any hereditary renal cancer predisposition syndromes. We evaluated the incidence other features across types. Methods: 463,546 clinically advanced (CAC) underwent hybrid...
7 Background: Nodal metastases from SCC are a clinical challenge in urologic and gynecologic oncology. Strategies employing CGP to identify targeted therapies for CUPs have shown potential; however, the molecular landscape of SCCUP remains poorly defined. We report results testing patients with SCCUPs identified Foundation Medicine, Inc. database, focus on those I/P/RP involvement. Methods: cases FoundationOneCDx (F1CDx) assay were based reported diagnosis CUP presence histology. After...
PURPOSE Although both urachal (U) and nonurachal (NU) bladder adenocarcinomas (adenoCas) share several histologic similarities, they differ in location sometimes therapeutic options. We analyzed the differences genomic alterations (GAs) between these tumor entities, with aim of identifying potential targets for clinical trials. MATERIALS AND METHODS Overall, 133 U 328 NU adenoCas were analyzed. Hybrid capture–based comprehensive profiling (CGP) was performed to evaluate all classes GA....